ALNEV Share Price

Open 0.81 Change Price %
High 0.83 1 Day 0.03 4.17
Low 0.74 1 Week 0.04 5.63
Close 0.75 1 Month -0.01 -1.32
Volume 6066034 1 Year 0.00 0.00
52 Week High 1.61
52 Week Low 0.66
ALNEV Important Levels
Resistance 2 0.83
Resistance 1 0.80
Pivot 0.77
Support 1 0.70
Support 2 0.67
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
DPT 0.26 100.00%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
CS 24.30 3.67%
More..
EPA France Top Gainers Stocks
DPT 0.26 100.00%
MLERO 0.34 25.93%
ALADO 0.05 25.00%
EMG 6.95 19.62%
EMG 6.95 19.62%
EMG 6.95 19.62%
EMG 6.95 19.62%
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
More..
EPA France Top Losers Stocks
ALDV 0.11 -15.38%
MLMGL 5.86 -9.85%
MLCMB 132.02 -8.94%
SFCA 2.09 -8.73%
SEC 0.59 -6.35%
SEC 0.59 -6.35%
ALINN 23.00 -6.08%
MLVIS 0.95 -5.94%
PGP 77.50 -5.83%
PGP 77.50 -5.83%
More..

Neovacs SA (EPA: ALNEV)

ALNEV Technical Analysis 2
As on 7th Dec 2016 ALNEV Share Price closed @ 0.75 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.94 & Buy for SHORT-TERM with Stoploss of 0.72 we also expect STOCK to react on Following IMPORTANT LEVELS.
ALNEV Target for December
1st Target up-side 0.76
2nd Target up-side 0.8
3rd Target up-side 0.84
1st Target down-side 0.66
2nd Target down-side 0.62
3rd Target down-side 0.58
ALNEV Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.neovacs.fr
ALNEV Address
ALNEV
3-5, Impasse Reille
Paris, 75014
France
Phone: 33 1 53 10 93 00
Fax: 33 1 53 10 93 03
ALNEV Latest News
Neovacs to attend Jefferies 2016 London Healthcare Conference November 16 17 2016   EconoTimes   - 03rd Nov 16
Stellar Board Member and Pharma Expert to Join Executive Team   Marketwired (press release)   - 24th Oct 16
Stellar Biotechnologies and Neovacs Announce Formation of New Company Neostell ...   Marketwired (press release)   - 19th Jul 16
Age Related Macular Degeneration Pipeline Landscape and Therapeutics Market ...   PR Newswire (press release)   - 08th Jul 16
Stellar Biotechnologies: Vaccine Tech Buoyed By Partnerships   Seeking Alpha   - 23rd Jun 16
Neovacs Reports Full Year 2015 Financial Results   GlobeNewswire (press release)   - 07th Mar 16
Neovacs Signs a Strategic Partnering Agreement With the Korean Company CKD ...   GlobeNewswire (press release)   - 15th Dec 15
Neovacs Establishes U.S. Subsidiary For Expansion Of Lupus Vaccine Candidate ...   Lupus News Today   - 18th Apr 15
Miguel Sieler, former Chairman and CEO Bayer France, named CEO of Neovacs   Business Wire (press release)   - 18th Oct 13
Making Biologic Drugs More Affordable   Drug Discovery & Development   - 13th Jul 10
Interactive Technical Analysis Chart Neovacs SA ( ALNEV EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Neovacs SA
ALNEV Business Profile
Neovacs S.A., a biotechnology company, focuses on active immunotherapy for autoimmune and inflammatory diseases in France. The company’s product pipeline comprises tumor necrosis factor kinoid for the treatment of rheumatoid arthritis and Crohn’s diseases; interferon a-kinoid to treat lupus; and vascular endothelial growth factor kinoid for the treatment of macular degeneration and cancer. Neovacs S.A. is based in Paris, France.